Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development

Rhea-AI Summary

Genentech (RO, ROG; RHHBY) collaborates with NVIDIA to leverage AI for drug discovery and development. The multi-year strategic research collaboration aims to accelerate the delivery of novel therapies and medicines to people by transforming AI models and algorithms into a next-generation AI platform.

Positive

• Collaboration with NVIDIA enhances Genentech's advanced AI research programs
• The partnership aims to optimize and scale Genentech's models using NVIDIA DGX Cloud
• Genentech's scientists are developing and leveraging AI and ML foundational models across diverse therapeutic modalities

Negative

• The PR does not provide specific data on the financial impact or projected outcomes of the collaboration

- Collaboration leverages expertise in artificial intelligence from Genentech and NVIDIA to unlock scientific innovation and empower R&D at a scale previously unattainable in pursuit of novel therapies -

- Multi-year research effort aims to optimize and accelerate each company’s platforms and create innovations that could be applied in healthcare and beyond -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development. The collaboration is designed to significantly enhance Genentech’s advanced AI research programs by transforming its generative AI models and algorithms into a next-generation AI platform, expediting the discovery and delivery of novel therapies and medicines to people.

The companies will join forces to accelerate and optimize Genentech’s proprietary machine learning (ML) algorithms and models on NVIDIA DGX Cloud, which provides a training-as-a-service platform built on dedicated NVIDIA AI supercomputing and software, including NVIDIA BioNemo for generative AI applications in drug discovery.

NVIDIA will share its computing expertise with Genentech’s teams of computational scientists with the goal of optimizing and scaling Genentech’s models, and in that process, may improve or enhance NVIDIA’s platforms.

“By harnessing the power of AI models and algorithms, with our unique data and experiments, we're unlocking scientific discoveries with incredible speed and generating insights at an unprecedented scale,” said Aviv Regev, EVP and head of Genentech Research and Early Development (gRED). “Bringing science and technology together has always been a foundation of biomedical breakthroughs at Genentech. We are thrilled to join forces with NVIDIA to further optimize our drug discovery and development to deliver treatments that transform people’s lives.”

“The greatest impact of generative AI is to revolutionize the life science and healthcare industry,” said Jensen Huang, founder and CEO of NVIDIA. “Our collaboration to create Genentech’s next-generation AI platform will dramatically accelerate the pace of drug discovery and development.”

The collaboration with NVIDIA complements Genentech’s AI/ML teams, which are developing and leveraging AI and ML foundational models across numerous research areas including diverse therapeutic modalities. Genentech scientists aim to glean new insights for target and drug discovery and to answer fundamental questions about human biology and disease.

The collaboration will also help accelerate Genentech’s “lab in a loop,” where extensive experimental data feeds computational models that uncover patterns and make new, experimentally testable predictions. Scientists quickly assess these predictions in the lab and the results are fed back into the models to improve the underlying computational model, allowing for iterative development of better therapies.

Activities will leverage publicly available and Genentech-proprietary data. Genentech will control the sharing of its proprietary data and NVIDIA will not have direct access to Genentech’s proprietary data unless granted by Genentech for use in a particular project during the term of that project.

Drug discovery and development is currently a lengthy, complicated, and uncertain process. Targets for novel medicines are difficult to predict, as is successfully developing a molecule as a potential therapeutic. Genentech believes that AI plays an invaluable role in revolutionizing drug development, in combination with people, science and technology, helping make it more predictable and cost-effective, boosting the success rate of R&D over the long term, and ultimately helping discover and design therapeutics to improve people’s lives.

About Genentech

Founded more than 45 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231121367977/en/

Media Contact:

Andrew Gordon

(650) 467-6800

Investor Contacts:

Loren Kalm

(650) 225-3217

Bruno Eschli

011 41 61 687 8503

Source: Genentech

FAQ

What is the collaboration between Genentech and NVIDIA about?

The collaboration aims to leverage AI for drug discovery and development to accelerate the delivery of novel therapies and medicines.

What are the key goals of the collaboration?

The collaboration aims to transform AI models and algorithms into a next-generation AI platform, optimize and scale Genentech's models using NVIDIA DGX Cloud, and develop AI and ML foundational models across diverse therapeutic modalities.

What expertise does Genentech bring to the collaboration?

Genentech brings its artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise to the collaboration.

How will NVIDIA contribute to the collaboration?

NVIDIA will share its world-leading accelerated computing capabilities and AI expertise to accelerate and optimize Genentech’s proprietary machine learning (ML) algorithms and models on NVIDIA DGX Cloud.

What are the potential benefits of the collaboration?

The collaboration aims to significantly enhance Genentech’s advanced AI research programs, expedite the discovery and delivery of novel therapies and medicines, and revolutionize the life science and healthcare industry.

What are Genentech's scientists aiming to achieve through AI and ML models?

Genentech's scientists aim to glean new insights for target and drug discovery and to answer fundamental questions across research areas including diverse therapeutic modalities.